A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy.
Adv Ther
; 38(6): 3203-3222, 2021 06.
Article
in En
| MEDLINE
| ID: mdl-33963971
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Muscular Atrophy, Spinal
/
Myostatin
Type of study:
Clinical_trials
/
Prognostic_studies
Limits:
Adult
/
Humans
Language:
En
Journal:
Adv Ther
Journal subject:
TERAPEUTICA
Year:
2021
Document type:
Article
Affiliation country:
United States
Country of publication:
United States